In The News :: ProMIS Neurosciences, Inc. (PMN)

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis" Click Here

Dec 18, 2018

ProMIS tackles Parkinson's and Alzheimer’s diseases

Dec 18, 2018

ProMIS Neurosciences (TSX:PMN): Targeting the root cause of Alzheimer’s and other neurodegenerative diseases

Sep 12, 2018

Stockhouse - The Key to Unlocking Alzheimers Treatment?

Sep 12, 2018

Global Business Report – Interview with Eugene Williams Executive Chairman, ProMIS

Aug 27, 2018

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

Jul 9, 2018

Why Hope Endures For An Alzheimer's Treatment — And Biogen Could Be First

Jun 21, 2018

ProMIS Trial Offers Hope For Alzheimer's Patients

Apr 19, 2018

Biocentury – Promis Identifies New Beta Amyloid Epitope To Treat AD

Mar 7, 2018

As Vtv data nearing in April, Promis AD bid a contender

Jan 13, 2018

ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds